Q: What are the practical aspects (i.e., birth weight, gestational age, etc.) of selecting which patients should receive supplementation in the neonatal intensive care unit (NICU)? A: Dr Bhatia: The primary criteria should be birth weight, not gestational age. If the patient is less than 1800 g, then premature infant formula is recommended. Alternatively, in breast-fed neonates, fortified breast milk should be administered for at least three months, preferably up to nine months. Owing to the difficulties associated with supplementation from the parent's standpoint, if by three months, the baby is growing above the 25th percentile, supplementation may be discontinued if it is deemed a hardship to continue. If the patient is growing above the 25th percentile, or if the neonate is term, above 3500 g and fully breast-fed, then supplementation may not be required. Gestational age is not a useful guideline to decide which babies should be supplemented, particularly in older 33 to 34 week babies. These older neonates typically thrive on breast milk alone and do not generally require supplementation. The only supplement recommended in this later subset of patients is vitamin D. Q: What is your advice regarding discharging breast-fed babies on six breast-feedings and two formula feedings per day considering that lactation consultants would disagree with this recommendation? How can neonatologists work with the consultants? A: Dr Bhatia: This was certainly a tough issue, but 20 years of research do not lie: premature babies that are strictly breastfed do not do well. Thus, one must negotiate with the lactation consultant to ensure the preemie is supplemented with either formula or a powder fortifier. Q: In reference to your recommended cocktail of 9 g of glucose, 1 g of lipids and 2 to 3 g of amino acids, how can the transient hyperglycemia noted in patients receiving the cocktail be avoided or managed? A: Dr Young: First, I do not recommend administering less than 4 mg/kg glucose in the cocktail (my recommendation delivers approximately 4.5 mg/kg glucose), and second, sometimes altering the dextrose concentration and decreasing the dextrose levels may be required. Finally, the combination of amino acids, essential fatty acids, ensuring adequate amounts of energy are provided as well as avoiding hyperglycemia is important, and should be achieved without the use of insulin. As routinely administering adequate amounts of amino acids, the number of babies that become hyperglycemic in my nursery are very small. Q: Is hyperglycemia an indication for the routine use of insulin? A: Dr Young: Insulin should not be routinely administered for the management of hyperglycemia or to promote growth, but insulin may be indicated in the treatment (but not the prevention of) hyperkalemia. Q: The first question asked of Dr Adamkin was related to the addition of docosa hexaenoic acid (DHA) and Arachdonic acid (ARA) to breast milk owing to the marked variability of DHA and ARA in different parts of the country in breast milk. A: Dr Adamkin: There are some trials currently being conducted in which pregnant women are being supplemented with DHA, and that this supplementation does lead to higher DHA levels at birth. Available evidence, while limited to date, indicates that cord blood levels of DHA and ARA can be increased via supplementation. It should be noted that more supplementation is not necessarily better, and that a saturation point at the cellular likely exists that remains to be elucidated. To date, it is unknown how much linolenic acid is being converted to DHA. Nonetheless, I am pleased that long-chain fatty acids have finally been added to infant formulas to better mimic human milk. Although some data suggests that DHA supplementation improves outcomes, firm data is lacking. Q: This question is related to growth velocity and what to advise community pediatricians regarding rate of growth considering the suggested relationship between low birth weight and adult onset chronic diseases. A: Dr Adamkin: If a preemie is not grown appropriately, the result will be either a lean, cognitively challenged child or an overweight, hypertensive child. Thus, I suggest that the primary concern should be cognition, and cardiovascular risk should be a lower priority. I am making this recommendation based on the NICHD network trial that provided goals for growth that two years later lead to less cerebral palsy (CP), higher scores on standardized examinations, and less retinopathy, blindness and hearing deficits.
